The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. Behandlung der Hautreaktionen bei EGFR-spezifischer Tumortherapie (Epidermaler Wachstumsfaktor Rezeptor)-Reference-Cited by-同舟云学术

The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. Behandlung der Hautreaktionen bei EGFR-spezifischer Tumortherapie (Epidermaler Wachstumsfaktor Rezeptor)

Published:2005-08 Issue:8 Volume:3 Page:599-606
ISSN:1610-0379
Container-title:Journal der Deutschen Dermatologischen Gesellschaft
language:en
Short-container-title:J Deut Dermatol Gesell

Author:

Segaert Siegfried,Tabernero Josep,Chosidow Olivier,Dirschka Thomas,Elsner Joern,Mancini Luca,Maughan Tim,Morere Jean-Franuois,Santoro Armando,Sobrero Alberto,Van Cutsem Eric,Layton Alison

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1610-0387.2005.05058.x/fullpdf

Reference37 articles.

1. The EGFR family and its ligands in human cancer

2. Anti-epidermal growth factor receptor drugs in cancer therapy

3. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy

4. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies

5. EGFR and cancer prognosis

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse effects of anti-cancer biologics on the ocular surface;Current Opinion in Allergy & Clinical Immunology;2024-07-04

2. Manifestaciones cutáneas asociadas al uso de cetuximab;Piel;2024-05

3. Acne;Rook's Textbook of Dermatology;2024-03-19

4. Prophylactic Effect of Nitric Oxide Donors on Rat Models of EGFR Inhibitor‒Induced Cutaneous Toxicities;Journal of Investigative Dermatology;2022-11

5. A phase 2 study for evaluating doxycycline 50 mg once daily and 100 mg once daily as preemptive treatment for skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy;Supportive Care in Cancer;2022-07-01